Secretary General of EASL; Director of the Centre for Liver and Gastrointestinal Research & Professor of Experimental Hepatology, University of Birmingham; Director of Midlands & Wales Advanced Therapy Treatment Centre; Deputy Director NIHR Birmingham Biomedical Research Centre; and Consultant Hepatologist at the Liver Unit, Queen Elizabeth Hospital Birmingham
Professor Newsome graduated Medical School, University of Edinburgh in 1995, and moved to Birmingham in 2007, to run the metabolic services at the Liver Unit, QEHB. His laboratory group focusses on identifying novel targets in the pathogenesis of NAFLD. He is the Co-ordinating Investigator for several global NAFLD studies, CI on studies of Fibroscan in NAFLD, and was CI on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapy in NAFLD, published in the Lancet.
Funded by EUFP7, MRC, Innovate UK, NIHR and MRC/Wellcome Clinical Training Fellowships, for three cutting edge clinical trials: REALISTIC, the largest clinical trial of haematopoietic stem cell therapy in patients with liver cirrhosis in Europe/US; MERLIN, a clinical trial of mesenchymal stromal cells in patients with primary sclerosing cholangitis; and POLARISE, a basket trial for patients with PSC, rheumatoid arthritis, Crohn’s disease and lupus nephritis.
He is editor of a textbook on Liver Transplantation, chaired the national guidelines for liver transplantation in NAFLD and sat on the NICE Guideline Development Group for NAFLD. He also led the UK multi-stakeholder guideline group on management of abnormal liver blood tests and has published over 100 research papers in scientific journals and many book chapters in the field of NAFLD.